Moderna, Inc.(MRNA)

NASDAQ Global Select
Sector: Healthcare | Industry: Biotechnology
Moderna, Inc. logo

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest News & Analysis

Moderna's challenges and opportunities: stock analysis, pipeline progress, and future prospects. Learn about MRNA's financial sustainability and investor sentiment.
Apr 9, 2025

Moderna (MRNA): Stock Decline, Pipeline Expansion, and Future Outlook

Moderna faces challenges including a Q1 2025 stock decline and regulatory uncertainty, but opportunities exist in pipeline expansion and the mRNA vaccine market.

Read more →
Moderna (MRNA) stock analysis: Insider confidence, patent disputes, and mRNA cancer vaccine potential.
Mar 14, 2025

Moderna (MRNA): Insider Buying, Patent Battles, and the Future of mRNA

Moderna navigates insider buying, patent battles, and mRNA cancer vaccine potential. Success hinges on market capitalization and financial sustainability.

Read more →
Moderna stock surge: Insider confidence, patent wins, and market momentum driving MRNA stock.
Mar 10, 2025

Moderna (MRNA): Decoding the Stock Surge, Patent Disputes, and mRNA Vaccine Race

Moderna's (MRNA) stock is surging amid insider buying and patent rulings, but faces competition and cash burn challenges. A deep dive into its prospects.

Read more →
Moderna (MRNA) stock analysis: Exploring mRNA cancer vaccine potential, patent battles, and future growth prospects.
Mar 6, 2025

Moderna (MRNA) Analysis: Cancer Vaccine, Patents, and Financials

Moderna's stock faces volatility despite insider buying and cancer vaccine progress. Patent battles and revenue shifts create uncertainty. A comprehensive analysis.

Read more →
Moderna faces patent lawsuits amidst RSV vaccine approval and bird flu funding uncertainty. Stock price analysis and future outlook.
Mar 3, 2025

Moderna's Crossroads: Patent Battles, RSV Market Entry, and Funding Challenges

Moderna faces patent lawsuits and funding uncertainty despite UK approval of its RSV vaccine. A deep dive into challenges and opportunities.

Read more →
Moderna (MRNA) stock analysis: Bird flu funding, mRNA competition, financial health, and future outlook.
Feb 28, 2025

Moderna (MRNA): Funding, Competition, and mRNA Vaccine Future

Moderna faces funding scrutiny and rising mRNA competition. Cost cuts, political shifts, and pipeline updates shape its future. Analyst outlook mixed.

Read more →
Moderna's post-pandemic strategy, pipeline, and financial outlook for 2025 analysis.
Feb 27, 2025

Moderna (MRNA): Navigating the Post-Pandemic Vaccine Market in 2025

Moderna is navigating a post-pandemic market with cost cuts and pipeline diversification amid competition and government funding uncertainties. Key developments and strategic implications analyzed.

Read more →
Moderna (MRNA) stock analysis: Pipeline diversification in RSV vaccine, cancer therapies, and financial outlook amidst mRNA competition.
Feb 26, 2025

Moderna (MRNA) Pipeline: RSV Vaccine, Cancer Therapies, and Financial Outlook

Analyzing Moderna's (MRNA) pipeline, including RSV and cancer vaccines, financial strategies, and international market performance. Get the latest insights on MRNA stock and industry trends.

Read more →
Moderna (MRNA) Stock Analysis: Market Volatility, Pipeline Updates, and Analyst Ratings
Feb 25, 2025

Moderna (MRNA): Analyzing Pipeline Progress, Financial Health, and Market Trends

Moderna (MRNA) navigates a dynamic market influenced by emerging diseases, competition, and analyst views. Pipeline progress and revenue are key.

Read more →
Moderna's Market Position: Stock price graph illustrating Moderna's financial performance and market trends post-pandemic.
Feb 21, 2025

Moderna Announces Major Business Developments | Latest Industry News

Moderna faces mixed analyst sentiment amid pipeline advancements and financial adjustments, influencing investor strategies.

Read more →
Moderna (MRNA) stock analysis: Navigating market challenges, pipeline expansion, and financial outlook for investors in 2025. Get insights on intraday performance, analyst sentiment, Q4 earnings, and future revenue projections.
Feb 20, 2025

Moderna Navigates Market Challenges: Pipeline Expansion and Financial Outlook

Moderna faces mixed investor sentiment as pipeline prospects compete with declining COVID-19 vaccine revenue, shaping intraday market dynamics and future outlook.

Read more →
Conceptual image of mRNA strand in a lab setting.
Feb 18, 2025

Moderna's Next Chapter: Post-COVID Challenges & Vaccine Hopes

A comprehensive analysis of Moderna’s mixed Q4 2024 results, cost-cutting, and diversified pipeline amid declining COVID-19 vaccine sales.

Read more →
Moderna logo in a lab setting.
Feb 17, 2025

Moderna's Q4 2024 Earnings: Mixed Financial Results

Moderna's Q4 2024 earnings beat revenue estimates amid higher losses and active pipeline diversification, revealing both challenges and opportunities.

Read more →
Moderna, Inc. (MRNA) News & Analysis | Monexa | Monexa